Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Overview of Exosomes01:36

Overview of Exosomes

3.8K
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
3.8K
Intralumenal Vesicles and Multivesicular Bodies01:38

Intralumenal Vesicles and Multivesicular Bodies

4.9K
Intraluminal vesicles (ILVs) are small vesicles 50-80 nm in diameter formed during the maturation of early endosomes. A specialized endosome containing numerous ILVs is called a multivesicular body (MVB). ILVs contain internalized molecules such as antigens, nucleic acids, proteins, and metabolites. Some of these molecules are released from the MVBs inside exosomes and are transported to other cells. Other MVBs contain molecules that are retained in the ILVs and are later degraded within the...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bilateral decompressive craniectomy in pediatric patients: A systematic review.

Neurosurgical review·2026
Same author

A phase I/II study of twice-weekly ixazomib plus pomalidomide and dexamethasone in relapsed and refractory multiple myeloma.

Haematologica·2026
Same author

Should checkpoint inhibitors be reserved for biomarker-selected pediatric brain tumors?

Journal of neuro-oncology·2026
Same author

Survival and prognostic factors of anaplastic hemangiopericytoma/solitary fibrous tumor grade III.

Acta neurochirurgica·2026
Same author

Comparative diagnostic capability of large language models in neurosurgery.

Journal of neurosurgery·2026
Same author

RNA transcripts in salivary extracellular vesicle cargo isolated from aged populations.

Frontiers in aging·2026
Same journal

A multicenter real-world study of clinical outcomes in octogenarians and older patients with acute myeloid leukemia.

Leukemia research·2026
Same journal

FLAMSA versus FLAG-IDA as salvage therapy in adults with relapsed/refractory acute myeloid leukemia and acute lymphoblastic leukemia: A single-center real-world retrospective study.

Leukemia research·2026
Same journal

CD244 modulates bone marrow infiltrating CD8<sup>+</sup> T cells and serves as a prognostic and immunotherapeutic target in acute myeloid leukemia.

Leukemia research·2026
Same journal

Long-term remission and survival in older adults with IDH-mutated acute myeloid leukemia treated with IDH inhibitors.

Leukemia research·2026
Same journal

Real-world outcomes of plasmablastic lymphoma: Treatment approaches and survival outcomes in the PLASMABLAT-001 cohort.

Leukemia research·2026
Same journal

CRS and ICANS as class-level adverse event for CD20 ×CD3 bispecific T-cell engagers: A Bayesian analysis of a nationwide database.

Leukemia research·2026
See all related articles

Related Experiment Video

Updated: Feb 17, 2026

Isolation and Analysis of Traceable and Functionalized Extracellular Vesicles from the Plasma and Solid Tissues
09:57

Isolation and Analysis of Traceable and Functionalized Extracellular Vesicles from the Plasma and Solid Tissues

Published on: October 17, 2022

2.8K

Extracellular vesicles in leukemia.

Alejandro Pando1, John L Reagan1, Peter Quesenberry1

  • 1Division of Hematology and Oncology, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, Providence, RI, USA.

Leukemia Research
|December 1, 2017
PubMed
Summary
This summary is machine-generated.

Leukemia extracellular vesicles (EVs) drive cancer progression and treatment evasion by altering the cellular microenvironment. These EVs offer potential for novel diagnostic and therapeutic strategies in leukemia treatment.

Keywords:
Acute myeloid leukemiaExosomesExtracellular vesiclesLeukemia EVsLeukemia exosomesLeukemia extracellular vesiclesMicrovesiclesRe-inductionResidual leukemia

More Related Videos

LINE-1 Methylation Analysis in Mesenchymal Stem Cells Treated with Osteosarcoma-Derived Extracellular Vesicles
12:18

LINE-1 Methylation Analysis in Mesenchymal Stem Cells Treated with Osteosarcoma-Derived Extracellular Vesicles

Published on: February 1, 2020

6.2K
Extraction of Extracellular Vesicles from Whole Tissue
09:03

Extraction of Extracellular Vesicles from Whole Tissue

Published on: February 7, 2019

16.2K

Related Experiment Videos

Last Updated: Feb 17, 2026

Isolation and Analysis of Traceable and Functionalized Extracellular Vesicles from the Plasma and Solid Tissues
09:57

Isolation and Analysis of Traceable and Functionalized Extracellular Vesicles from the Plasma and Solid Tissues

Published on: October 17, 2022

2.8K
LINE-1 Methylation Analysis in Mesenchymal Stem Cells Treated with Osteosarcoma-Derived Extracellular Vesicles
12:18

LINE-1 Methylation Analysis in Mesenchymal Stem Cells Treated with Osteosarcoma-Derived Extracellular Vesicles

Published on: February 1, 2020

6.2K
Extraction of Extracellular Vesicles from Whole Tissue
09:03

Extraction of Extracellular Vesicles from Whole Tissue

Published on: February 7, 2019

16.2K

Area of Science:

  • Biomedical Sciences
  • Oncology
  • Cell Biology

Background:

  • Extracellular vesicles (EVs) are key mediators of intercellular communication, carrying molecular cargo from parent cells.
  • Leukemia-derived EVs significantly influence tumor progression and contribute to therapeutic resistance.
  • Understanding leukemia EVs is crucial for developing effective cancer treatments.

Purpose of the Study:

  • To review the role of EVs in leukemia.
  • To explore how leukemia EVs modulate the tumor microenvironment, hematopoiesis, and immune responses.
  • To discuss current and future EV-based therapeutic applications in leukemia.

Main Methods:

  • Literature review of studies on extracellular vesicles in leukemia.
  • Analysis of the mechanisms by which leukemia EVs impact the tumor microenvironment.
  • Examination of the potential of EVs as diagnostic markers and therapeutic agents.

Main Results:

  • Leukemia EVs promote a pro-cancerous microenvironment through cell-to-cell communication.
  • EVs contribute to immune evasion and altered hematopoiesis in leukemia.
  • The cargo of leukemia EVs influences various cellular processes, facilitating malignancy.

Conclusions:

  • Leukemia EVs play a multifaceted role in promoting cancer progression and immune evasion.
  • EVs represent promising candidates for developing novel diagnostic and therapeutic strategies for leukemia.
  • Further research into EV biology is essential for advancing leukemia treatment.